10-Q: InMed Pharmaceuticals Reports Q3 2024 Results, Highlights Progress in Alzheimer's and AMD Programs

InMed Pharmaceuticals released its Q3 2024 financial results, showcasing revenue growth in its commercial segment and advancements in its pharmaceutical research programs.

Summary

• InMed Pharmaceuticals reported a net loss of $5.7 million for the nine months ended March 31, 2024, compared to a $7.6 million loss in the same period of 2023.
• The company's accumulated deficit reached $107.1 million as of March 31, 2024.
• Revenue for the nine months ended March 31, 2024, was $3.3 million, up from $1.8 million in the same period of 2023, primarily driven by the BayMedica commercial segment.
• The company's cash, cash equivalents, and short-term investments totaled $7.6 million as of March 31, 2024.
• InMed expects its current cash reserves to fund operations into the fourth quarter of calendar 2024.
• The company has raised $4.7 million through a private placement in the nine months ended March 31, 2024.
• Research and development expenses decreased to $2.6 million for the nine months ended March 31, 2024, compared to $3.1 million in the same period of 2023.
• The company has identified a material weakness in its internal controls over financial reporting.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the company's research programs and commercial segment, the significant losses, going concern warning, and material weakness in internal controls raise serious concerns about the company's financial health and future prospects. The need for additional capital is also a significant risk.

Positives

• BayMedica's revenue increased significantly, indicating growth in the commercial segment.
• Positive preclinical data for INM-901 and INM-089 suggests potential for future therapeutic applications.
• The appointment of Dr. David G. Morgan to the Scientific Advisory Board adds expertise to the Alzheimer's program.
• The company secured additional time to meet Nasdaq's minimum bid price requirement.

Negatives

• The company continues to incur significant operating losses and has an accumulated deficit of $107.1 million.
• There is substantial doubt about the company's ability to continue as a going concern within one year.
• The company has identified a material weakness in its internal controls over financial reporting.
• The company's cash reserves are expected to fund operations only into the fourth quarter of calendar 2024.

Risks

• The company's future viability depends on its ability to raise additional capital.
• The company may not be able to obtain financing on acceptable terms, or at all.
• The terms of any financing may adversely affect the holdings or rights of existing shareholders.
• The company is subject to risks and uncertainties associated with drug development and commercial growth.
• The company's ability to generate product revenue is dependent on the success of its products in the health and wellness sector and the commercialization of its drug candidates.
• The company has a material weakness in its internal controls over financial reporting.

Future Outlook

The company expects its current cash reserves to fund operations into the fourth quarter of calendar 2024, depending on the level and timing of BayMedica revenues and operating expenses. The company plans to continue advancing its drug candidates and manufacturing technologies, seeking regulatory approvals, and exploring strategic partnerships.

Management Comments

• Eric Hsu, InMed's SVP of Preclinical Drug Development, commented, 'We are privileged to welcome someone of Dr. Morgans stature to our SAB, which underscores the recent progress we've achieved in the INM-901 program.'
• Eric Hsu also stated that Dr. Morgans guidance and expertise will be invaluable as they advance to the next stages of development of their INM-901 program in the treatment of Alzheimers.

Industry Context

The company is operating in the competitive pharmaceutical and biotechnology industries, focusing on rare cannabinoids and proprietary cannabinoid analogs. The company's focus on Alzheimer's and AMD aligns with the growing need for treatments in these areas. The company's manufacturing capabilities in rare cannabinoids also position it in the growing health and wellness sector.

Comparison to Industry Standards

• InMed's revenue growth in its commercial segment is a positive sign, but its overall financial performance is still weak compared to established pharmaceutical companies.
• The company's research and development spending is lower than many of its peers, which may impact its ability to advance its drug candidates.
• The company's cash position is relatively low, raising concerns about its ability to fund its operations and research programs.
• The company's material weakness in internal controls is a concern and needs to be addressed to meet industry standards for financial reporting.
• Compared to companies like GW Pharmaceuticals (now part of Jazz Pharmaceuticals) which successfully commercialized cannabinoid-based drugs, InMed is still in the early stages of development and commercialization.
• In comparison to companies like Alnylam Pharmaceuticals, which focuses on RNAi therapeutics, InMed's approach with small molecule drug candidates is different, but both face similar challenges in clinical development and regulatory approvals.
• Compared to companies like Amylyx Pharmaceuticals, which recently gained FDA approval for an ALS drug, InMed is still in the preclinical and early clinical stages for its programs.

Management Changes

Legal Proceedings

• BayMedica received a letter from a licensor alleging a breach of a patent license agreement, which BayMedica disputes.
• The company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of business.

Related Party Transactions

• Norton Rose Fulbright Canada LLP, where director Janet Grove is a partner, provided legal services to the company for $197,155 during the nine months ended March 31, 2024.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional capital.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers of BayMedica may be impacted by changes in the company's operations or product offerings.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.
• The company's ability to develop and commercialize new treatments could impact patients who may benefit from cannabinoid-based pharmaceutical drugs.

Next Steps

• The company will continue to advance its INM-755 program for the treatment of EB and other dermatological conditions.
• The company will continue to advance research with proprietary drug candidates in the INM-901 program targeting treatment of neurodegenerative diseases and in the INM-089 program to treat dry AMD.
• The company will investigate its Product Candidates for additional uses beyond their initial target indications.
• The company will pursue the discovery of additional small molecule drug candidates for other diseases with high unmet medical needs.
• The company will seek regulatory approvals for any Product Candidates that successfully complete clinical trials.
• The company will scale-up its manufacturing processes and capabilities, or arrange for a third party to do so on its behalf.
• The company will continue to support its commercial operations and revenue-generating Products at BayMedica.
• The company will execute on business development activities, including but not limited through strategic transactions, mergers, acquisitions and/or divestitures as well as inor out-licensing of technologies or business units.
• The company will maintain, expand, enforce, defend and protect its intellectual property.
• The company will continue to further advance the research and development of various manufacturing technologies.
• The company will build internal infrastructure, including personnel, to meet its milestones.
• The company will add operational, financial and management information systems and personnel, including personnel to support product development and potential future commercialization efforts and its operations as a public company.

Key Dates

Keywords

InMed Pharmaceuticals, Alzheimer's disease, Age-related macular degeneration, Rare cannabinoids, Pharmaceuticals, Clinical trials, BayMedica, INM-901, INM-089, Financial results, Drug development, Biotechnology